Reduced-intensity allogeneic stem cell transplantation (RIST) is usually reserved for patients with mantle cell lymphoma who relapse after an autoSCT. However, the long-term efficacy of RIST and its curative potential have not been clearly demonstrated. We studied the long-term outcome of patients receiving a RIST for MCL as reported to the EBMT. A total of 324 patients, median age 57 years (range 31-70), underwent a RIST between 2000 and 2008; 43% of the patients had received >3 lines of prior therapy, including an autoSCT in 46%. Non-relapse mortality (NRM) was 10% at 100 days and 24% at 1 year and was lower for patients receiving anti-thymocyte globulin (ATG)/ALG (RR 0.59, p = 0.046). After a median follow-up of 72 months (range 3-159), 118 patients relapsed at a median of 8 months post RIST (range 1-117). The cumulative incidence of relapse was 25% and 40% at 1 and 5 years, respectively, and was associated with chemorefractory disease (HR 0.49, p = 0.01) and the use of CAMPATH (HR 2.59, p = 0.0002). The 4-year progression-free survival rate and overall survival rate was 31 and 40%, respectively. RIST results in long-term disease-free survival in about 30% of the patients, including those patients relapsing after a prior autoSCT.
Introduction
Mantle cell lymphoma (MCL) is an uncommon form of non-Hodgkin's lymphoma that has been associated with chemorefractoriness and, relative to other lymphoma subtypes, a poor prognosis. For younger transplant-eligible patients with symptomatic or progressive disease, the standard of care has been to deliver intensive induction therapy incorporating cytarabine and Rituximab, followed by high-dose therapy (HDT) and an autologous stem cell transplant (autoSCT) [1, 2] . This approach has been shown to improve progression-free survival (PFS) when compared to less intensive therapy [3] and prolong median survival to beyond 7 years [4] [5] [6] [7] [8] . With longer-term follow-up, it is apparent, however, that most patients relapse following this intensive first-line approach and further therapy is required [9, 10] .
Allogeneic stem cell transplantation (alloSCT) offers the theoretical benefits of the provision of a graft that is uncontaminated by lymphoma, a low risk of therapy-related myelodysplastic syndrome/acute myeloid leukaemia (MDS/ AML) and the development of a graft versus lymphoma effect. The majority of the patients with MCL are not eligible for a myeloablative alloSCT due to age and comorbidities. Several groups have therefore studied the role of reduced-intensity conditioning allogeneic stem cell transplantation (RIST) in MCL and reported variable outcomes [11] [12] [13] [14] [15] . Most of these studies included small numbers of patients and with relatively short follow-up, so the toxicity and curative potential of RIST in MCL remains controversial. To better determine the role of RIST in the management of MCL, we have therefore conducted retrospective registry analysis of the largest cohort of patients and with the longest follow-up reported to date.
Methods
The EBMT is a voluntary organisation comprising over 600 transplant centres mainly from Europe. The member centres are required to submit the minimal essential data (Med-A form) from consecutive patients to a central lymphoma registry. Participating transplant centres are subject to onsite audits to assess data accuracy and consecutive reporting.
Patient eligibility
All patients who had undergone a RIST for MCL using a sibling or unrelated donor from January 2000 to December 2008 and had been registered with the EBMT were eligible. The patients undergoing planned tandem autologous transplants followed by RIST or cord blood transplants were excluded. The minimum data required for the inclusion of a patient in the study were age, sex, histological diagnosis, date of diagnosis, prior autoSCT, disease status at alloSCT, reduced-intensity conditioning regimen, date of transplantation, type of donor, date of follow-up, disease status at last follow-up, date of disease progression or death and cause of death. Informed consent was obtained according to the local regulations applicable at the time of transplantation. Since January 1 2003, it has been a requirement that all EBMT centres should have obtained a written informed consent prior to data registration.
Study definitions
RIST was defined according to published EBMT criteria as follows: Busulphan ≤8 mg/kg ± TBI ≤6 cGy (fractionated) ± purine analogue ± ATG; cyclophosphamide ≤60 mg/kg ± TBI ≤6 cGy (fractionated) ± purine analogue ± ATG; melphalan 70-140 mg/m 2 ± purine analogue ± campath 1H. Disease status at transplantation was considered chemosensitive if patients had achieved a response (i.e. complete remission (CR), partial remission (PR), complete remission unconfirmed (CRu), very good partial response (VGPR) and sensitive relapse/progression) to the last therapy prior to transplantation. Chemosensitive patients were separated into those who were in 1st chemosensitive response at RIST independent of the number of regimens needed to achieve this status, i.e. this group could also include primary refractory patients (chemosensitive 1st response), and those patients who were in 2nd or higher chemosensitive response at RIST (chemosensitive >1st response). Chemorefractory disease included all primary refractory and relapsed patients who had shown either no response or progressive disease following the last therapy prior to transplantation. Good performance status was defined as Karnofsy score >80% or ECOG score 0-1.
Statistical analysis
PFS was measured in months as the time from the day of transplantation until disease relapse/progression or death from any cause. The probabilities of PFS and overall survival (OS) were calculated using the Kaplan-Meier product-limit estimate. Non-relapse mortality (NRM) included all deaths with no prior progression/relapse occurring at any time after RIST. The risk of developing acute or chronic graft-versus-host disease (GVHD), the rate of NRM and disease relapse/progression were calculated using cumulative incidence analysis to take into account the competing risks. The following variables were studied for associations with transplant outcomes: year of RIST, age at diagnosis, age at transplant, gender, stage at diagnosis, number of prior lines of therapy, Rituximab prior to RIST, prior autoSCT (yes or no), time to relapse following autoSCT, time from diagnosis to RIST, performance status at RIST, disease status at RIST, donor type, stem cell source, T-cell depletion, donor/recipient gender, ABO compatibility, donor/recipient cytomegalovirus (CMV) status and type of reduced intensity conditioning (RIC) regimen. The log-rank test was used to analyse associations with PFS and OS and Cox univariate analysis for associations with disease relapse/progression and NRM. Any factors showing a significant impact or a trend to an impact in the univariate analysis (p < 0.15) and additional variables of clinical interest were entered into a multivariate analysis. Multivariate analyses were performed using Cox proportional hazards regression employing a stepwise conditional backward method. A separate category for missing data was created for some variables. The proportional hazard assumption was tested for all variables in the selected models by introducing time as a (time-dependent) covariate and testing for a significant interaction. If a deviation from the proportionality assumption was found, a stratified Cox model was used. The final model was tested for interactions between variables.
The impact of acute and chronic GVHD on disease relapse/progression was investigated using a timedependent Cox model. To further investigate the impact of chronic GVHD on relapse/progression, a landmark analysis was used. All statistical analyses were performed using SPSS version 13.0 (SPSS Inc., Chicago, IL) except for the cumulative incidence analyses that were performed with the NCSS97 (Number Cruncher Statistical System, Kaysville, Utah).
Results

Patient characteristics
Between January 2000 and December 2008, 220 centres reported 795 patients to the EBMT registry who met the inclusion criteria for this study. The minimum essential data required for entry to the study was available in 324 patients (from 135 centres) who form the study population. The pretransplant characteristics of the 324 patients are illustrated in Table 1 . The 471 patients with incomplete data were analysed as a separate cohort and compared to the study group. No difference in pre-transplant characteristics, NRM, PFS or OS between these two groups could be demonstrated (data not shown).
Non-relapse mortality
There were 98 deaths attributed to NRM occurring at a median of 4.5 months following transplant. The following specific causes of NRM were reported: GVHD, 16; infection, 33; GVHD and infection, 36; multi-organ failure, 6; graft rejection, 3; other causes, 3; unknown, 1. The Long-term outcome analysis of reduced-intensity allogeneic cumulative incidence of NRM at 100 days and 1 year were 10% and 24%, respectively (Fig. 1) . In univariate and multivariate analyses, only the use of ATG/ALG was associated with a significantly lower risk of NRM (Tables 2  and 3 ). Patient age, poor performance Status (PS) at SCT, prior autoSCT and donor type had no significant impact on the NRM.
Graft-versus-host disease
Acute GVHD (aGVHD) developed in 170 patients (grade I 52, grade II 52, grade III-IV 64, grade unknown 2) at a median of 32 days post transplant. The cumulative incidence of aGVHD was 52% at 100 days post transplant. In multivariate analysis, use of CAMPATH in the conditioning regimen was associated with a lower risk of aGVHD (HR 0.46, CI 0.27-0.77, p = 0.004). Older age and chemosensitive disease were also associated with a lower risk of aGVHD. Chronic GVHD (cGVHD) developed in 111 (45 limited cGVHD, 66 extensive cGVHD) of 261 patients at risk of this complication with a cumulative incidence of 41% at 12 months post transplant.
Disease relapse/progression
With a median follow-up of 72 months (range 3-159 months), 118 patients have experienced relapse or progression at a median of 8 months (range 1-117) after RIST. There were two relapse events occurring after 5 years post RIST amongst 59 patients at risk. The cumulative incidence of disease relapse/progression was 25% at 12 months and 40% at 5 years (Fig. 2) . In multivariate analysis, refractory disease at transplant, T-cell depletion with CAMPATH and use of TBI in the conditioning were associated with a significantly higher risk of disease relapse/progression, whereas treatment with Rituximab prior to the RIST was associated with a significantly lower risk of relapse (Table 3) . In a landmark analysis, the development of either aGVHD or cGVHD by The following variables were studied for their influence on transplant outcomes: year of RICalloSCT, age at diagnosis, age at transplant, sex, stage and B symptoms at diagnosis, number of prior lines of therapy, prior autologous transplant, time to relapse following autologous transplant, time from diagnosis to RICalloSCT, performance status at transplant, disease status at transplant, donor type, stem cell source, T-cell depletion, donor/ recipient sex, ABO compatibility, donor/recipient CMV status, type of RIC regimen 
Progression-free and overall survival
The Kaplan-Meier estimate of PFS at 1 and 4 years post transplant was 51% and 31%, respectively (Fig. 3) . In multivariate analysis, chemorefractory disease at transplant and three or more prior lines of therapy were associated with a significantly worse PFS (Fig. 3a and Table 3 ). The Kaplan-Meier estimate of OS at 1 and 5 years post transplant was 62% and 40%, respectively (Fig. 4 ) and was significantly worse in patients with chemorefractory disease at transplant (Fig. 4a and Table 3 ). There was no difference in PFS or OS for patients who had received the RIST in 1st chemosensitive response when compared to patients receiving a RIST later in their disease course (Figs. 3b and  4b ). Likewise, a prior autoSCT had no influence on the PFS or OS in the univariate and multivariate analyses.
Discussion
This study provides a long-term follow-up of the largest cohort of patients with MCL who have undergone a RIST investigated to date. A number of investigators have previously published their experience of RIST in MCL describing smaller cohorts of patients (n = 33-202) [11] [12] [13] [14] [15] [16] [17] with shorter follow-up (25-56 months). The results reported in these previous studies were variable with between 9% and 25% of patients succumbing to NRM and between 15% and 38% experiencing disease relapse or progression. In the present study, we observed a 1-year NRM rate of 24%, similar to that reported in some of the studies previously mentioned. Most of the cases of NRM were attributable to the well-recognised complications of GVHD and infection. Of note, the NRM rate was not influenced by patient age, PS, donor type or exposure to previous high-dose therapy, demonstrating the feasibility of RIST in these settings. An unexpected finding was the apparent protective effect of ATG/ALG in reducing the NRM. Relapse remains the major challenge following a RIST, and in our current series, 40% of the patients had relapsed/ progressed by 5 years following the transplant, similar to data previously reported [11] [12] [13] [14] [15] [16] [17] . In keeping with a smaller previous study from Seattle [13] , the long-term follow-up of the current series demonstrates that relapse events are extremely rare beyond 5 years post transplant. This observation also applies to patients who have relapsed after a prior autoSCT. The finding that in vivo T-cell depletion with CAMPATH was associated with a greater risk of relapse supports the notion of an allogeneic graft-versus-MCL effect in line with previous reports [11, 12, 15] . Further studies are required to determine if a lower dose of CAMPATH or alternatively the use of ATG/ALG would be optimal [18, 19] .
The current standard first-line therapy in transplanteligible candidates with MCL is induction therapy followed by an autoSCT [3, 7, 20] . This approach leads to prolonged remissions particularly in patients with low-and intermediate-risk disease as defined by the MIPI, although a continual pattern of relapse is subsequently observed [9] . However, first-line autoSCT consolidation is less effective in patients with high-risk disease [9] and for such patients, alternative frontline therapies are required. The British Society Of Bone Marrow Transplantation has recently completed a prospective trial of first-line consolidation with a BEAM-CAMPATH conditioned alloSCT and described a 2-year NRM and PFS rate of 13.5% and 68%, respectively [21] . The CIBMTR has reported that for patients undergoing an alloSCT after only 1 or 2 lines of prior therapy (and no prior autoSCT), the relapse risk following a RIST was only 15% compared with 32% for those undergoing an autoSCT. However, in the CIBMTR study, the benefit of a lower relapse rate after a RIST was offset by a higher NRM so that there was no difference in survival compared to an autoSCT [12] . Whether a RIST can produce better outcomes than an autoSCT in patients with high-risk disease features (for example high MIPI, Ki67 and blastoid variants) in the first-line setting remains to be determined in prospective trials. However, due to the toxicity observed in this and other studies, for the time being, RIST cannot be recommended as a routine part of first-line therapy where autoSCT remains the consolidation procedure of choice.
Patients who have relapsed after an autologous transplant generally have a poor prognosis and may be offered a variety of alternative treatment strategies including novel agents. The BTK inhibitor ibrutinib has been used in patients with relapsing MCL producing excellent responses with very acceptable toxicity [22, 23] . However, the duration of response is short and patients failing ibrutinib have a dismal prognosis [24, 25] , suggesting that ibrutinib might be used best in this setting as a bridge to an alloSCT. The data reported in the current study suggest that in patients who relapse after an autologous transplant, approximately 30% will achieve long-term disease-free survival with an alloSCT. Whether ibrutinib has a role post RIST to prevent relapse and the comorbidity associated with cGVHD requires further study [26] .
The major limitation of this study is its retrospective registry basis, which may result in deficiencies in the data provided despite the requirement for participating centres to submit sequential transplant data and to participate in onsite audits to check data accuracy. We have not been able to collect adequate data to calculate the MIPI score as such data were not required for the registration of the patients. Further, this study has only analysed transplants performed prior to 2008 and therefore may not be representative of patients treated according to the current practice. However, by the same token, this has enabled us to analyse the long follow-up of a large cohort of patients undergoing a RIST and to characterise their outcomes.
In summary, this study provides useful information to guide clinicians in the management of patients with MCL. The plateau in the relapse curve demonstrates that RIST may be a curative procedure in MCL even in patients who have relapsed after a prior autoSCT. Future studies should explore how a RIST can be combined with innovative targeted and cellular therapies aimed at the eradication of MCL.
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